DHEA
Dehydroepiandrosterone, adrenal androgen precursor
Written by Aaron CuhaReviewed Sep 2026
Also known as: Dehydroepiandrosterone, DHEA-S, Prasterone
The hormone whose decline with age is the most-cited reason to supplement it, tested repeatedly in randomised trials, and mostly unimpressive outside two specific populations.
Overview
DHEA is the most abundant circulating steroid in the human body and its levels fall steeply from the twenties onward, which is why it became the original anti-ageing hormone supplement. It is also the clearest case on this site of the pattern the whole site argues against: a hormone declines with age, therefore replacing it should reverse ageing, therefore sell it.
It has been tested a great deal. A meta-analysis of randomised placebo-controlled trials examined bone mineral density in healthy adults, which is the endpoint the decline argument most directly predicts, and the results are far weaker than the rationale.
Where it does have support is narrower and specific: it is an approved prescription product as prasterone for moderate to severe dyspareunia due to vulvar and vaginal atrophy in postmenopausal women, applied locally rather than taken systemically, and it has a role in some fertility protocols.
Unlike everything else in this batch it is sold as a supplement in the United States, which means it is also the one most people can buy without meeting a doctor.
Mechanism of action
A 19-carbon steroid produced mainly by the adrenal cortex, circulating largely as the sulphate DHEA-S. It has weak direct androgen receptor activity and acts mostly as a precursor, converted in peripheral tissues into testosterone and then oestradiol. That peripheral conversion is the whole story and the whole problem: how much any individual converts, and into which hormone, depends on the enzyme activity of their tissues, so the same oral dose produces very different hormonal exposure in different people, and in women it raises testosterone substantially more than in men. The locally applied vaginal product works by converting to active hormones within the tissue itself with limited systemic exposure, which is a different intervention from swallowing it.
Human evidence
Extensively tested for general anti-ageing use with unimpressive results, and separately approved for one specific local indication where the delivery route is the point.
- Pooled randomised placebo-controlled trials have examined bone mineral density in healthy adults, the endpoint the decline rationale most directly predicts.
- Prasterone, DHEA delivered as a vaginal insert, is FDA-approved for moderate to severe dyspareunia due to menopausal vulvar and vaginal atrophy. Local delivery with limited systemic exposure is a different intervention from an oral capsule.
- It is used in some fertility protocols, where the evidence is contested rather than settled.
- Peripheral conversion means the same oral dose produces very different hormone exposure between individuals, and considerably more testosterone in women than in men.
- It is prohibited in sport by the World Anti-Doping Agency.
- It is prescription-only in the United Kingdom, Australia and Canada, and a freely sold supplement in the United States, which is a striking regulatory divergence for the same molecule.
What this does not tell you: The general anti-ageing case is the weakest part and has had the most testing, which is the relevant combination. Because the effect depends entirely on individual peripheral conversion, group averages in trials may obscure real responders and non-responders, and no clinical test identifies which you are. Women should note that oral DHEA raises testosterone considerably more than it does in men, so virilising effects are a genuine consideration rather than a theoretical one. And the approved vaginal product's evidence does not transfer to swallowing a supplement.
Reading the research record
DHEA is the template for a mistake this site documents repeatedly, and it is worth naming because the same reasoning is currently being applied to newer molecules.
The argument runs: this substance is abundant in youth, it falls steeply with age, the fall correlates with things that get worse with age, therefore restoring it should restore those things. It is intuitive and it has been wrong often enough that it should be treated as a hypothesis rather than a conclusion. Growth hormone followed the same arc. Melatonin, in part. Testosterone partly escaped it only because someone eventually ran a 5,246-person trial.
What survived for DHEA is instructive: not the systemic anti-ageing use that motivated all the research, but a local vaginal preparation for a specific menopausal symptom, where the delivery route is the active ingredient in the idea. That is usually how these stories end when they end well.
One regulatory note worth carrying. The same molecule is a freely sold supplement in the United States and a prescription-only medicine in the United Kingdom, Australia and Canada. Regulators looking at the same evidence reached opposite conclusions about whether people should be able to buy it unsupervised.
The evidence, charted
Fig. 1 · evidence composition
0of 1 citation (0%) is in people
Every citation cited here is Review work; no other study type is cited on this page. This count is of our own citation list and understates any literature larger than the sources we cite.
Fig. 2 · evidence over time
Every citation here was published in 2019.
Too few distinct publication years on this page to plot as a timeline. The newest citation on file is from 2019, more than five years ago; the published record may have gone quiet.
Fig. 3 · legal status at a glance
US
Not approved
UK
Prescription
AU
Prescription
CA
Prescription
Approved in 0 of 4, prescription route in 3, not approved in 1. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Key studies & citations
- Review2019
A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA supplementation of bone mineral density in healthy adults
Pooled randomised placebo-controlled evidence on the endpoint the age-decline argument most directly predicts. Bone density is where a replaced androgen precursor should show up if the reasoning holds, which makes this the right test of the general supplementation case rather than of a specific indication.
Gynecological Endocrinology
Frequently asked questions
Does DHEA slow ageing?
The rationale is that levels fall steeply with age, and the testing has not matched the rationale. Randomised placebo-controlled trials pooled for bone mineral density in healthy adults address the endpoint the argument most directly predicts, and the general anti-ageing case is the most tested and least supported part of this compound's record.
What is it actually approved for?
As prasterone, a vaginal insert for moderate to severe painful intercourse caused by menopausal vulvar and vaginal atrophy. The delivery route is central: the hormone converts to active forms inside the tissue with limited systemic exposure. That approval does not support swallowing a capsule.
Why do different countries treat it so differently?
Because they reached opposite conclusions about the same evidence. It is a freely sold supplement in the United States and a prescription-only medicine in the United Kingdom, Australia and Canada. If you assumed supplement status meant a regulator had judged it safe for unsupervised use, three other regulators disagree.
Is it different for women?
Yes, and in a way that matters. DHEA is a precursor converted in tissue, and oral dosing raises testosterone considerably more in women than in men. Acne, hair growth and voice change are real considerations rather than theoretical ones, and voice change in particular does not reverse.
Will it show up on a drug test?
Yes. It is prohibited in sport by the World Anti-Doping Agency, and its supplement status in the United States does not change that.